Gyre Therapeutics (GYRE) Misses Q3 EPS by 2c

Gyre Therapeutics (NASDAQ: GYRE) reported Q3 EPS of $0.03, $0.02 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $30.56 million versus the consensus estimate of $33.55 million.

For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.

You May Also Be Interested In

• Aggreko files for proposed IPO
• DA Davidson Starts Armstrong World Industries (AWI) at Neutral
• Supreme Court lifts decision that blocked in 23 states and Washington, D.C. Trump's order restricting mail-in ballots